USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
21ST CENTURY THERAPEUTICS, INC.
Address:
1366 HILTON RD
FERNDALE, MI 48220-2837
Phone:
N/A
URL:
N/A
EIN:
138331643
DUNS:
968109702
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,292,603.00 4
SBIR Phase II $1,133,678.00 1

Award List:

Novel Small-molecule TNF-a Modulators as Chemoprotective Agents

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$154,852.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprote ctive agent which reduces the side effects… More

Novel small-molecule TNF-a modulators as chemoprotective agents

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,133,678.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – 313-870-1741
Abstract:
DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprotective agent which reduces the side effects… More

TAS::75 0849::TAS

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$186,857.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – 313-874-6798
Abstract:
Radiotherapy can potentially inflict serious damage on healthy normal organs. For example, pneumonitis and fibrosis are two well-recognized adverse effects from lung cancer radiotherapy: Currently, amifostine (Ethyol) is the only approved radioprotector indicated to reduce xerostomia associated with… More

Development of a novel small molecule, UTL-5g, to treat oxaliplatin-induced throm

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$276,418.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – (734) 330-6052
Abstract:
DESCRIPTION (provided by applicant): Although oxaliplatin is a third-generation platinum drug, it has become the most prescribed amongst all platinum drugs overtaking its predecessors, cisplatin and carboplatin. To date, oxaliplatin has become an integralpart of various chemotherapy protocols,… More

Development of a Novel ELISA Kit for Screening Potential JAK3 Inhibitors

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$674,476.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – 734-330-6052
Abstract:
DESCRIPTION (provided by applicant): Janus kinase 3 (JAK3) is an intracellular kinase involved in cytokine and antibody receptor signaling; it is frequently over-activated during the course of inflammatory autoimmune diseases. Therefore, suitable JAK3 inhibitors that modulate the overexpression of… More